OpenAI, the developer of ChatGPT, has made a couple of big hires as it prepares for a major expansion into healthcare.

FDA clears AI-powered glucose monitoring app. The clearance marks a first for an over-the-counter tool in this category.

Tech vendor Reveleer and policy analytics firm Mathematica released their 2025 State of Technology in Value-Based Care report, the findings of which show that AI adoption in healthcare is widespread—but integration is spotty. 

Most organizations trying out generative AI—a full 95%—are failing to receive a measurable return on the pilot investment. 

If three sticking points aren’t unstuck soon, older Americans won’t benefit much by the 1,000+ medical devices that, as of 2025, are both equipped with AI and cleared by the FDA. 

"Eko is transforming how we detect cardiovascular disease—making cutting-edge, AI-powered tools accessible to frontline providers," said former U.S. Surgeon General Jerome Adams, MD.

A new generation of AI-native researchers is leading the way in the war on cancer. This next crop of scientists is AI-native, interdisciplinary—and comfortable challenging assumptions. 

The roots of medicine are in the promotion of human welfare, aka humanitarianism. Healthcare AI can either degrade or reinforce this heritage. Who picks the path? 

If not for off-limits data, AI might have a decent shot at curing cancer. 

Nurse leaders seeking AI acceptance from those they lead would do well to apply psychological insights along with technical tips.